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Abstract: Abstract  
Background 
Nearly 20% of women presenting with breast cancer in the UK are of 
reproductive age. The aim of our study was to assess fertility outcome in 
relation to intent to conceive in patients who had completed breast 
cancer treatment.  
Methods  
Between July 2011 and December 2013, women, aged less than 43 years at 
the time of diagnosis, were asked during their follow-up in breast cancer 
clinic, to complete a questionnaire on intentions to conceive and 
pregnancy outcome.  
Results  
A total of 175 women completed the questionnaire at a median time of 6 
years from time of diagnosis. Their median age at the time of diagnosis 
was 37 years and at the time of the survey was 43 years. At the time of 
the survey, 42% (72/175) had completed their family, 41% (72/175) 
reported that they would like to have children and 4% (7/175) did not 
wish to have children. Twenty-seven respondents had actively tried to 
conceive, and of those 13 (48%) had a live birth. There were 12 
unintended pregnancies; the majority of which were terminated (58% 
(7/12)) with only 3 live births. Among those who did not wish to 
conceive, only 32% (36/111) reported using contraception.  
Conclusion 
This is a retrospective study investigating menstrual function, 
contraceptive methods and fertility outcomes of young breast cancer 
survivors. This study highlights the need for healthcare professionals to 
provide long-term contraceptive advice to women who do not wish to 
conceive. 
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Abstract  
Background 
Nearly 20% of women presenting with breast cancer in the UK are of reproductive 
age. The aim of our study was to assess fertility outcome in relation to intent to 
conceive in patients who had completed breast cancer treatment.  
Methods  
Between July 2011 and December 2013, women, aged less than 43 years at the time 
of diagnosis, were asked during their follow-up in breast cancer clinic, to complete a 
questionnaire on intentions to conceive and pregnancy outcome.  
Results  
A total of 175 women completed the questionnaire at a median time of 6 years from 
time of diagnosis. Their median age at the time of diagnosis was 37 years and at the 
time of the survey was 43 years. At the time of the survey, 42% (72/175) had 
completed their family, 41% (72/175) reported that they would like to have children 
and 4% (7/175) did not wish to have children. Twenty-seven respondents had actively 
tried to conceive, and of those 13 (48%) had a live birth. There were 12 unintended 
pregnancies; the majority of which were terminated (58% (7/12)) with only 3 live 
births. Among those who did not wish to conceive, only 32% (36/111) reported using 
contraception.  
Conclusion 
This is a retrospective study investigating menstrual function, contraceptive methods 
and fertility outcomes of young breast cancer survivors. This study highlights the 
need for healthcare professionals to provide long-term contraceptive advice to women 
who do not wish to conceive. 
 
Keywords: unplanned pregnancies, breast cancer survivors, contraception, pregnancy 
rate 
 
 
 
 
 
Dear Reviewers, 
 
Thank you very much for your valuable comments. Please see below our replies to 
your queries and suggestions. 
 
 
 
Reviewer #1: The present paper entitled "Planned and unplanned pregnancies in 
breast cancer survivors" is a retrospective survey investigating menstrual function, 
use of contraceptive methods and fertility outcomes according to patients' wish in 
young breast cancer survivors.   The following points should be addressed:   
 
1) Being the main topic of the current study, the issue of safety of pregnancy in breast 
cancer survivors should be discussed more in detail. Despite the high percentage of 
patients wishing to have a pregnancy after breast cancer (Letourneau et al, Cancer 
2012) as also shown in this study, breast cancer patients are among cancer survivors 
those with the lowest pregnancy rate (Peccatori et al, Ann Oncol 2013). An issue of 
great importance in this field is that both patients (Senkus et al, Psycho Oncol 2014) 
and physicians (Biglia et al, Gynecol Endocrinol 2015 & Lambertini et al, Breast 
2018) remain concerned on the potential detrimental prognostic effect of pregnancy in 
breast cancer survivors. This is not supported by recent data showing the safety of 
pregnancy after prior history of breast cancer (Hartman et al, Breast Cancer Res Treat 
2016 & Iqbal et al, JAMA Oncol 2017 & Lambertini et al, J Natl Cancer Inst 2018 & 
Lambertini et al, Cancer 2019). In addition, a trial (POSITIVE study) is currently 
investigating the safety of interrupting endocrine therapy for allowing patients to have 
a pregnancy (Pagani et al, Breast 2015). This important point needs to be stressed 
more in depth.  
 
Thank you very much for your very valuable and important comments. We have 
added these points in the main manuscript. 
 
 2) Response rate is not reported. How many patients were surveyed?   
 
Since the questionnaire was handed in in the waiting room before their follow up 
appointment, all patients returned the questionnaires.  
3) In both the text (including abstract) and table 2, not only absolute numbers but also 
percentages should be reported for the sake of clarity. Since the denominator varies in 
the different analysis, reporting both absolute numbers and percentages could help the 
readers to have a quicker understanding of the data.  
 
Thank you very much for this suggestion. We have added as requested. 
 
4) Some missing references that could be included are: -Epidemiology of cancer in 
young adult women: Fidler et al, Lancet Oncol 2017; -Gonadotoxicity of anticancer 
therapies in breast cancer patients: Lambertini et al, Current Opin Oncol 2018 & 
Codacci-Pisanelli et al, Crit Rev Oncol Hematol 2017.  
 
-Suboptimal use of contraception in breast cancer survivors: Villareal-Garza et al, J 
Global Oncol 2018. – 
*Revision Note
Instead of current reference 16, the most updated guidelines on this topic should be 
cited: Peccatori et al, Breast 2013 & Paluch-Shimon et al, Breast 2017 & Oktay et al, 
J Clin Oncol 2018.   
 
All above-mentioned references are added 
 
5) The graphical quality of both figures is poor; they should be improved for example 
by using colors and clearer text. In figure 2, the use of percentages and not only 
absolute numbers could be helpful.  
We are sorry, our original file has very clear font and colours, but it seems that there 
is a technical error that might have occurred during conversion into pdf format. 
We will try again to upload the images.  
We have added percentage in figure 2.  
   
6) The abstract should be divided into the usual 4 sections (background, methods, 
results and conclusions) for the sake of clarity.     
Thank you, amendments are done. 
 
 
 
Reviewer #2: The authors present the results of survey of breast cancer survivors, 
exploring fertility issues in women in their early 40's.  The manuscript is well written 
and concise. It provides an interesting insight into return of menses and fertility in 
these women.  Before publication, I would recommend that the following issues be 
addressed:  
 
-can you provide information about whether the unintentional pregnancies occurred in 
women taking tamoxifen/ endocrine therapy? The tamoxifen group is particularly at 
risk of pregnancy and may be advised to have termination if they become pregnant.  
This issue of tamoxifen and pregnancy planning and the challenge of whether to take 
women off therapy to conceive should be mentioned. Balance between declining 
fertility and cancer treatment.   
 
Thank you for your question. None of the patients who had termination were on 
endocrine therapy. 
 
-add % to Table 2   
Thank you, we have done it 
-Table 3 doesn't enhance the paper; very generic table re contraception; suggest 
authors consider whether it should be kept.  
Thank you very much for your advice, but we still feel that this table is useful for the 
audience of this journal since it includes the team who is looking after breast cancer 
patient. And even though we would not anticipate oncologist, surgeons or breast 
nurses to prescribe contraception, but it would be important if this team is aware of 
the methods and could prompt their patient to seek advice appropriately form GP or 
family planning clinics.  
 
-Please acknowledge the important role of the GP in cancer survivorship and 
contraception counselling; it could be argued that a GP could be more helpful than a 
gynaecologist for these patients.   
 Thank you, we have added about the role of GPs in our manuscript. However, we still 
believe that the main message here is for the cancer team to remind patients about 
importance of contraception, since GP may not necessary have direct interaction with 
these patients to have opportunity to discuss or advice on this matter. And certainly 
the role of gynaecologists here would be the least, since they are least likely to have 
interactions with breast cancer patients, unless patients were referred to them.  
 
-Statistical methods description- add description of p-value calculations.   
Thank you. We have added description 
-you talk about hormonal contraception then about LNG-IUS as if they are different; 
LNG-IUS is a form of hormonal contraception; did you mean oral contraceptives in 
the first comment? 
We have made modifications, thank you. 
Highlights:  
   �  At least 40% of women diagnosed wit breast cancer 
under the age of 43 still desire to conceive after completing 
cancer treatment    
   �  Large proportion of women who did not use 
contraception in spite of having regular periods and reporting 
no intention to conceive    
   �  This study established an unexpected high 
proportion of unintended pregnancies, 58% of which required 
terminated    
   �  Its imperative for healthcare professionals to provide 
patients with advice not only on fertility but also 
contraception during and after chemotherapy    
 
*Highlights (for review)
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Introduction     
Breast cancer is the most common cancer of women in the UK, with 1 in 8 developing this dis-
ease in their lifetime [1,2].  Approximately 23% of in situ cases and 19% of invasive breast 
cancer cases are diagnosed in premenopausal women [3]. 
Despite the increasing incidence, as a result of improved screening programmes and advances 
in treatment, more than 81% of women with early breast cancer survive more than ten years [4]. 
Current family planning trends show that women are delaying pregnancies until their late 30-
40s [5], which is demonstrated by the rate of live births to mothers aged 35 and over in UK ris-
ing from 8.7% in 1990 to 20% in 2012 [6].  Similar trends are demonstrated throughout the 
USA [7] and the rest of the world [8]. Hence an increasing proportion of women diagnosed with 
breast cancer now have not attempted to conceive at the time of their diagnosis.   
Despite high rates of women wishing to achieve pregnancy after breast cancer, up to 47% in 
some cases [9], breast cancer survivors are amongst cancer survivors with the lowest pregnancy 
rates [10], and 70% lower than the general population [11]. It is thought this is secondary to a 
number of factors including: the frequent use of gonadotoxic chemotherapy which can cause 
permanent amenorrhoea with complete loss of germ cells, transient amenorrhoea, menstrual ir-
regularity and subfertility [12]. The degree of damage depends on the type of agent, patient age, 
original ovarian reserve, dose and duration of treatment [13]. Pregnancy is strongly discouraged 
during chemotherapy and radiotherapy as there is a higher risk of congenital malformations and 
spontaneous abortion [14].   
In addition to receiving gonadotoxic treatment which can reduce the future conception rate, 
women are advised to avoid becoming pregnant for at least 18 months to two years when the 
risk of recurrence is at its highest. Patients often have prolonged treatment periods with 
tamoxifen in endocrine-sensitive disease and current practice is to advise against pregnancy in 
this period [10]. Finally, patients [15], as well as physicians [16][17], appear to remain con-
cerned that pregnancy could simulate cancer recurrence. Recent studies contradict this hypothe-
*Manuscript - final, changes and corrections marked
Click here to view linked References
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sis [18]. Conversely, pregnancy has been hypothesized as a protective factor against breast can-
cer [19,20, 21]. Iqbal [19] et al found that the 5 year survival rate amongst women who became 
pregnant 6 month or more after their breast cancer diagnosis was 96.7% compared with 87.5% 
for women with no pregnancy. The POSITIVE study is currently investigating the safety of in-
terrupting endocrine therapy  to allow patients to attempt to conceive [22].       
Although there are data on successful pregnancies after breast cancer, and that childbirth after 
diagnosis and treatment of early breast outcome does not affect outcome, there are only a few 
studies in the literature which look at fertility intent. Moreover, to the best of our knowledge 
none have followed up these women for longer than 10 years.   
The aim of our study was to assess fertility outcome in relation to intent in women who had a 
diagnosis of early breast cancer during reproductive age.  
 
Methods   
Between August 2011 and October 2013, female cancer survivors who were diagnosed with 
early breast cancer up to 42 years of age (inclusive) were approached with a questionnaire dur-
ing their follow-up visit to the breast clinic at Guy’s and St Thomas NHS Foundation Trust.  
The questionnaire (Appendix 1) was constructed by a multi-disciplinary team involving medical 
oncologists, a nurse consultant in breast cancer and a reproductive medicine gynecologist. The 
questionnaire contained 19 questions covering different aspects of menstrual and reproductive his-
tory at the time of diagnosis, and then at the time of the questionnaire: menstrual cycle history, on-
going use of contraception, subsequent pregnancies and their outcomes. In addition, we asked if the 
patient had completed their family, or wished to have further children in those who had children, or 
who wanted children or were actively trying to conceive if they had been childless prior to diagno-
sis. We also explored if patients were told about the potential effect of their cancer treatment on fer-
tility, if they felt they were provided with sufficient information, and if fertility preservation was 
offered.  
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This service evaluation was approved by the Guy’s and St Thomas’ Foundation Trust Audit Com-
mittee. Verbal informed consent was obtained from each patient. 
Statistical analysis 
All data were coded and checked for errors. Missing and ambiguous responses were excluded from 
analysis. Descriptive statistics (i.e. frequency distribution, mean [standard deviation (SD)], and me-
dian [range]) were used to summarise characteristics and outcome variables. Differences between 
continuous and categorical variables were tested using T-test and the χ2 test respectively. For all 
analyses, p <0.05 was considered statistically significant.  
Results   
Characteristics of responders 
We collected questionnaires from 175 patients. The primary diagnosis of breast cancer for these 
women was made between 1995 and 2012. The details of the responders are given in Table 1. The 
response rate was 100% as everyone who was approached in the clinic agreed to fill in a question-
naire, however, not all the responders answered all questions therefore absolute numbers and fig-
ures have been given to aid analysis of the results. The median age at diagnosis was 37 (25 to 42) 
years. At the time of this survey the median follow-up from diagnosis was 6 (1 to 21) years. The 
median age at the time of the survey was 43 (30-55) years. As many as 75% (131/175) of the wom-
en had chemotherapy as part of their breast cancer treatment and 33% (55/163) were still undergo-
ing anti-breast cancer hormone treatment at the time of the survey (Table 1).  
Fertility history at diagnosis  
Prior to the diagnosis of breast cancer, 65% (113/175) of the responders stated they had been preg-
nant resulting in a live birth in 50% (87/175). In our cohort, the average reported age of conception 
prior to cancer diagnosis was 25 years. 
4 of 12 
Menstrual function before and after breast cancer treatment 
Most women, 90% (158/175), were having periods at the time of breast cancer diagnosis; four pa-
tients were peripartum 2% (4/175). Of the patients who had adjuvant chemotherapy, 56% (74/131) 
reported that their periods had restarted after chemotherapy (Table 1). 21% (28/131) of patients in 
this cohort reported no periods after chemotherapy. As expected there was a significant difference 
(P<0.0001) in age at the time of diagnosis between patients who recovered their menstrual function 
after chemotherapy (35.94.4 years) and those who did not (39.42.2 years).  
Contraception after treatment  
Women were asked about current contraceptive use and their intention to conceive (Table 2). 64% 
(74/116) reported they were not using any form of contraception at the time of the survey despite 
not wanting to conceive. Of those not using contraception 46% (53/116) reported having their last 
period within last month. The median age of women not using contraception was 44 (34 to 55 
years), with 85% (99/116) being under 50 years.  
Desire to conceive and pregnancies after diagnosis   
At the time of the survey, 42% (74/175) of women had completed their family; 4% (7/175) did not 
want children. 41% (72/175) wanted to have/or had more children. 20 women did not answer this 
question. 74% (120/164; 11 did not answer) of women stated they had a discussion with a clinician 
about their fertility. Of 175 responders, 14 had their embryos/eggs frozen.  
Following the diagnosis, at the time of questionnaire, 26 women reported achieving a pregnancy 
with 16 of them resulting in a live birth (Figure 1). Not all conceptions were intentional. Among 27 
women who had been trying to conceive, 13 had live births (two women were also pregnant at the 
time of the survey and six women had had a previous miscarriage*, with none of the patients having 
termination of pregnancy). Conversely, among 12 women who became pregnant unintentionally,  
* some miscarriages and live birth were reported by the same patients 
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there were seven terminations, two miscarriages and only three live births. None of the patients who 
had termination were receiving tamoxifen or any other endocrine therapy.  
Discussion  
To the best of our knowledge this is one of the first studies assessing fertility outcome in relation 
to patients’ intent.  This study demonstrates that as many as 41% (72/175) of patients wanted to 
have children or more children after cancer treatment. However, only 37% (27/72) of those who 
wanted children have attempted to conceive so far, and of these almost half of them 48% 
(13/27) have been successful with a live birth.  
Conversely, there was a high rate of pregnancy termination in patients who conceived uninten-
tionally. Unexpectedly, a large proportion of patients who reported not using any contraception 
at the time of the survey, have also acknowledged that they did not want a child or more chil-
dren.  
The particular strength of this study is the length of follow-up of these women at a median of 6 
years and up to 21 years. Moreover, 75% (131/175) of the women in our study had chemotherapy as 
part of their breast cancer treatment and 33% (55/163) were still receiving anti-breast cancer endo-
crine treatment at the time of the survey. This highlights the need for ongoing discussions with 
younger patients regarding fertility.  
The retrospective nature of our study means that pregnancy age trends in our study may not be rep-
resentative of trends in 2019. In our cohort the average age of having children was 25.8 years old, 
which is younger in comparison to the current average of 30.3 years [22]. In our study, 41% 
(72/175) of the women wanted a baby after breast cancer diagnosis. Due to the increasing trend of 
delaying pregnancy, a higher rate of women without children at breast cancer diagnosis is to be ex-
pected. Therefore, the rate of women wishing to retain fertility at breast cancer diagnosis may now 
be higher. Furthermore, with the increasing input from Assisted Conception Units over the last 10 
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to 15 years the pregnancy rate after breast cancer is likely to be higher.  Only 14 women had em-
bryo preservation in our cohort. At the time of questionnaire none of these patients had used their 
stored embryos. 
A recent systematic review quotes pregnancy rates following breast cancer to be 3-14% [24].  The 
pregnancy rate after breast cancer in our study was much higher at 52% (14/27) but this is likely to 
be because our assessment was based on intention to conceive and the long follow-up, whereas the 
above-mentioned meta-analysis quoted the pregnancy rate in relation to a total number of patients 
who had breast cancer without adjusting for patients’ intention to conceive.  
Our study also raises a concern about the rate of unintended pregnancies in this population of pa-
tients. Pregnancy during breast cancer treatment should be avoided; not only can cancer treatment 
be teratogenic to the unborn child but also the emotional distress and difficult decision-making can 
have adverse psychological consequences for the women involved. A recent meta-analysis of 16 
studies showed that 21% of women with a diagnosis of breast cancer terminated their subsequent 
pregnancies [25]. 
Contraceptive counselling is important, however little research has been done to establish 
whether patients take contraception to avoid pregnancies during this time and what advice 
should be given. Moreover, there is little data on unplanned pregnancies and their outcome. A 
large Australian population-based study showed that 47% of pregnancies that occurred 2 years 
following a breast cancer diagnosis were terminated [26], and that the rate of abortion was in-
versely proportional to the length of time between breast cancer diagnosis and subsequent pregnan-
cy.  However, authors could only speculate about the reasons behind this trend, one of which 
was failure of contraception.  
Multiple studies have emphasised the importance of fertility counselling, but few have investigated 
contraceptive counselling in these women [13,26]. A retrospective Swiss study of 100 patients dur-
ing their first year after breast cancer diagnosis found that circumstances leading to two unintended 
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pregnancies in their cohort included ineffective contraceptive methods, poor communication, and 
misinterpreting treatment-related amenorrhoea for the menopause [26]. Another cohort study of 104 
breast cancer women in Mexico also reported poor counselling and low use of appropriate contra-
ception during chemotherapy [27].  
In our study, we found that 66% (116/175) of women at the time of the survey were not using any 
contraception. More surprisingly, 64% (74/116) of the women who did not use contraception did 
not intend to conceive, despite 42 % (31 out of 74) of them reporting having periods. Clinicians 
have improved counselling young breast cancer patients about fertility preservation [28, 29, 30], but 
a recent study showed that although oncologists felt the issue of contraception was an important as-
pect of discussion in breast cancer surveillance, only 30% of respondents said that they actively en-
quired about use of contraception [31]. Hormonal contraception, in the form of oral contraception 
or levonorgestrel intrauterine system (LNG- IUS), are relatively contraindicated in women with 
breast cancer, particularly those with oestrogen receptor positive cancer, and it is usually discontin-
ued. Women may not want to start a new form of contraception whilst undergoing such major 
changes in their lives, therefore clinicians need to explain to patients the importance of contracep-
tion during breast cancer treatment and then plan for long-term contraception after definitive treat-
ment, particularly in those women who have completed their family or do not wish to conceive. 
Oncologists are not necessarily experts on long-term methods of contraception and women may 
benefit from referral to gynaecologists. Moreover, better education should be given to general prac-
titioners on contraceptive methods after malignancy as they are the first port of call for the patient 
for long-term or ongoing contraceptive advice. The current guideline of Faculty of Sexual and Re-
productive Health on contraceptive choices after treatment of breast cancer recommends non-
hormonal methods [32].  
 Use of Levonorgestrel Intrauterine System (LNG-IUS) is not usually recommended during breast 
cancer treatment, but can be used post breast cancer treatment with specialist advice sought if other 
more appropriate methods are not available or not acceptable. Table 3 outlines the different meth-
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ods of contraception and their pros and cons, this is adapted from the Faculty of Sexual and Repro-
ductive Healthcare guidelines. 
 The limitation of our study was that this was a retrospective questionnaire relying on women to re-
call facts from sometimes many years ago, and was therefore subject to recall and self-reporting 
bias. Although the data was collected from a large tertiary unit with a diverse population, the cohort 
was still limited to those patients living in the South East of England.    
This study has highlighted the importance of ongoing fertility counselling in those women who 
wish to conceive, and in particular contraceptive counselling in those who do not. We must 
adopt an approach of having frank discussions with our patients at the time of diagnosis, and on 
follow-up, so we are able to tailor their treatment to encompass issues of fertility and prevent 
unintended pregnancies.  
Specific questions and information regarding fertility and contraception should be part of the rou-
tine follow-up care and information offered to all patients of reproductive age following treatment 
for breast cancer. 
 
Disclosure: The authors have declared no conflicts of interest 
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Introduction     
Breast cancer is the most common cancer of women in the UK, with 1 in 8 developing this dis-
ease in their lifetime [1,2].  Approximately 23% of in situ cases and 19% of invasive breast 
cancer cases are diagnosed in premenopausal women [3]. 
Despite the increasing incidence, as a result of improved screening programmes and advances 
in treatment, more than 81% of women with early breast cancer survive more than ten years [4]. 
Current family planning trends show that women are delaying pregnancies until their late 30-
40s [5], which is demonstrated by the rate of live births to mothers aged 35 and over in UK ris-
ing from 8.7% in 1990 to 20% in 2012 [6].  Similar trends are demonstrated throughout the 
USA [7] and the rest of the world [8]. Hence an increasing proportion of women diagnosed with 
breast cancer now have not attempted to conceive at the time of their diagnosis.   
Despite high rates of women wishing to achieve pregnancy after breast cancer, up to 47% in 
some cases [9], breast cancer survivors are amongst cancer survivors with the lowest pregnancy 
rates [10], and 70% lower than the general population [11]. It is thought this is secondary to a 
number of factors including: the frequent use of gonadotoxic chemotherapy which can cause 
permanent amenorrhoea with complete loss of germ cells, transient amenorrhoea, menstrual ir-
regularity and subfertility [12]. The degree of damage depends on the type of agent, patient age, 
original ovarian reserve, dose and duration of treatment [13]. Pregnancy is strongly discouraged 
during chemotherapy and radiotherapy as there is a higher risk of congenital malformations and 
spontaneous abortion [14].   
In addition to receiving gonadotoxic treatment which can reduce the future conception rate, 
women are advised to avoid becoming pregnant for at least 18 months to two years when the 
risk of recurrence is at its highest. Patients often have prolonged treatment periods with 
tamoxifen in endocrine-sensitive disease and current practice is to advise against pregnancy in 
this period [10]. Finally, patients [15], as well as physicians [16][17], appear to remain con-
cerned that pregnancy could simulate cancer recurrence. Recent studies contradict this hypothe-
*Manuscript - final, unmarked
Click here to view linked References
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sis [18]. Conversely, pregnancy has been hypothesized as a protective factor against breast can-
cer [19,20, 21]. Iqbal [19] et al found that the 5 year survival rate amongst women who became 
pregnant 6 month or more after their breast cancer diagnosis was 96.7% compared with 87.5% 
for women with no pregnancy. The POSITIVE study is currently investigating the safety of in-
terrupting endocrine therapy  to allow patients to attempt to conceive [22].       
Although there are data on successful pregnancies after breast cancer, and that childbirth after 
diagnosis and treatment of early breast outcome does not affect outcome, there are only a few 
studies in the literature which look at fertility intent. Moreover, to the best of our knowledge 
none have followed up these women for longer than 10 years.   
The aim of our study was to assess fertility outcome in relation to intent in women who had a 
diagnosis of early breast cancer during reproductive age.  
 
Methods   
Between August 2011 and October 2013, female cancer survivors who were diagnosed with 
early breast cancer up to 42 years of age (inclusive) were approached with a questionnaire dur-
ing their follow-up visit to the breast clinic at Guy’s and St Thomas NHS Foundation Trust.  
The questionnaire (Appendix 1) was constructed by a multi-disciplinary team involving medical 
oncologists, a nurse consultant in breast cancer and a reproductive medicine gynecologist. The 
questionnaire contained 19 questions covering different aspects of menstrual and reproductive his-
tory at the time of diagnosis, and then at the time of the questionnaire: menstrual cycle history, on-
going use of contraception, subsequent pregnancies and their outcomes. In addition, we asked if the 
patient had completed their family, or wished to have further children in those who had children, or 
who wanted children or were actively trying to conceive if they had been childless prior to diagno-
sis. We also explored if patients were told about the potential effect of their cancer treatment on fer-
tility, if they felt they were provided with sufficient information, and if fertility preservation was 
offered.  
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This service evaluation was approved by the Guy’s and St Thomas’ Foundation Trust Audit Com-
mittee. Verbal informed consent was obtained from each patient. 
Statistical analysis 
All data were coded and checked for errors. Missing and ambiguous responses were excluded from 
analysis. Descriptive statistics (i.e. frequency distribution, mean [standard deviation (SD)], and me-
dian [range]) were used to summarise characteristics and outcome variables. Differences between 
continuous and categorical variables were tested using T-test and the χ2 test respectively. For all 
analyses, p <0.05 was considered statistically significant.  
Results   
Characteristics of responders 
We collected questionnaires from 175 patients. The primary diagnosis of breast cancer for these 
women was made between 1995 and 2012. The details of the responders are given in Table 1. The 
response rate was 100% as everyone who was approached in the clinic agreed to fill in a question-
naire, however, not all the responders answered all questions therefore absolute numbers and fig-
ures have been given to aid analysis of the results. The median age at diagnosis was 37 (25 to 42) 
years. At the time of this survey the median follow-up from diagnosis was 6 (1 to 21) years. The 
median age at the time of the survey was 43 (30-55) years. As many as 75% (131/175) of the wom-
en had chemotherapy as part of their breast cancer treatment and 33% (55/163) were still undergo-
ing anti-breast cancer hormone treatment at the time of the survey (Table 1).  
Fertility history at diagnosis  
Prior to the diagnosis of breast cancer, 65% (113/175) of the responders stated they had been preg-
nant resulting in a live birth in 50% (87/175). In our cohort, the average reported age of conception 
prior to cancer diagnosis was 25 years. 
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Menstrual function before and after breast cancer treatment 
Most women, 90% (158/175), were having periods at the time of breast cancer diagnosis; four pa-
tients were peripartum 2% (4/175). Of the patients who had adjuvant chemotherapy, 56% (74/131) 
reported that their periods had restarted after chemotherapy (Table 1). 21% (28/131) of patients in 
this cohort reported no periods after chemotherapy. As expected there was a significant difference 
(P<0.0001) in age at the time of diagnosis between patients who recovered their menstrual function 
after chemotherapy (35.94.4 years) and those who did not (39.42.2 years).  
Contraception after treatment  
Women were asked about current contraceptive use and their intention to conceive (Table 2). 64% 
(74/116) reported they were not using any form of contraception at the time of the survey despite 
not wanting to conceive. Of those not using contraception 46% (53/116) reported having their last 
period within last month. The median age of women not using contraception was 44 (34 to 55 
years), with 85% (99/116) being under 50 years.  
Desire to conceive and pregnancies after diagnosis   
At the time of the survey, 42% (74/175) of women had completed their family; 4% (7/175) did not 
want children. 41% (72/175) wanted to have/or had more children. 20 women did not answer this 
question. 74% (120/164; 11 did not answer) of women stated they had a discussion with a clinician 
about their fertility. Of 175 responders, 14 had their embryos/eggs frozen.  
Following the diagnosis, at the time of questionnaire, 26 women reported achieving a pregnancy 
with 16 of them resulting in a live birth (Figure 1). Not all conceptions were intentional. Among 27 
women who had been trying to conceive, 13 had live births (two women were also pregnant at the 
time of the survey and six women had had a previous miscarriage*, with none of the patients having 
termination of pregnancy). Conversely, among 12 women who became pregnant unintentionally,  
* some miscarriages and live birth were reported by the same patients 
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there were seven terminations, two miscarriages and only three live births. None of the patients who 
had termination were receiving tamoxifen or any other endocrine therapy.  
Discussion  
To the best of our knowledge this is one of the first studies assessing fertility outcome in relation 
to patients’ intent.  This study demonstrates that as many as 41% (72/175) of patients wanted to 
have children or more children after cancer treatment. However, only 37% (27/72) of those who 
wanted children have attempted to conceive so far, and of these almost half of them 48% 
(13/27) have been successful with a live birth.  
Conversely, there was a high rate of pregnancy termination in patients who conceived uninten-
tionally. Unexpectedly, a large proportion of patients who reported not using any contraception 
at the time of the survey, have also acknowledged that they did not want a child or more chil-
dren.  
The particular strength of this study is the length of follow-up of these women at a median of 6 
years and up to 21 years. Moreover, 75% (131/175) of the women in our study had chemotherapy as 
part of their breast cancer treatment and 33% (55/163) were still receiving anti-breast cancer endo-
crine treatment at the time of the survey. This highlights the need for ongoing discussions with 
younger patients regarding fertility.  
The retrospective nature of our study means that pregnancy age trends in our study may not be rep-
resentative of trends in 2019. In our cohort the average age of having children was 25.8 years old, 
which is younger in comparison to the current average of 30.3 years [22]. In our study, 41% 
(72/175) of the women wanted a baby after breast cancer diagnosis. Due to the increasing trend of 
delaying pregnancy, a higher rate of women without children at breast cancer diagnosis is to be ex-
pected. Therefore, the rate of women wishing to retain fertility at breast cancer diagnosis may now 
be higher. Furthermore, with the increasing input from Assisted Conception Units over the last 10 
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to 15 years the pregnancy rate after breast cancer is likely to be higher.  Only 14 women had em-
bryo preservation in our cohort. At the time of questionnaire none of these patients had used their 
stored embryos. 
A recent systematic review quotes pregnancy rates following breast cancer to be 3-14% [24].  The 
pregnancy rate after breast cancer in our study was much higher at 52% (14/27) but this is likely to 
be because our assessment was based on intention to conceive and the long follow-up, whereas the 
above-mentioned meta-analysis quoted the pregnancy rate in relation to a total number of patients 
who had breast cancer without adjusting for patients’ intention to conceive.  
Our study also raises a concern about the rate of unintended pregnancies in this population of pa-
tients. Pregnancy during breast cancer treatment should be avoided; not only can cancer treatment 
be teratogenic to the unborn child but also the emotional distress and difficult decision-making can 
have adverse psychological consequences for the women involved. A recent meta-analysis of 16 
studies showed that 21% of women with a diagnosis of breast cancer terminated their subsequent 
pregnancies [25]. 
Contraceptive counselling is important, however little research has been done to establish 
whether patients take contraception to avoid pregnancies during this time and what advice 
should be given. Moreover, there is little data on unplanned pregnancies and their outcome. A 
large Australian population-based study showed that 47% of pregnancies that occurred 2 years 
following a breast cancer diagnosis were terminated [26], and that the rate of abortion was in-
versely proportional to the length of time between breast cancer diagnosis and subsequent pregnan-
cy.  However, authors could only speculate about the reasons behind this trend, one of which 
was failure of contraception.  
Multiple studies have emphasised the importance of fertility counselling, but few have investigated 
contraceptive counselling in these women [13,26]. A retrospective Swiss study of 100 patients dur-
ing their first year after breast cancer diagnosis found that circumstances leading to two unintended 
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pregnancies in their cohort included ineffective contraceptive methods, poor communication, and 
misinterpreting treatment-related amenorrhoea for the menopause [26]. Another cohort study of 104 
breast cancer women in Mexico also reported poor counselling and low use of appropriate contra-
ception during chemotherapy [27].  
In our study, we found that 66% (116/175) of women at the time of the survey were not using any 
contraception. More surprisingly, 64% (74/116) of the women who did not use contraception did 
not intend to conceive, despite 42 % (31 out of 74) of them reporting having periods. Clinicians 
have improved counselling young breast cancer patients about fertility preservation [28, 29, 30], but 
a recent study showed that although oncologists felt the issue of contraception was an important as-
pect of discussion in breast cancer surveillance, only 30% of respondents said that they actively en-
quired about use of contraception [31]. Hormonal contraception, in the form of oral contraception 
or levonorgestrel intrauterine system (LNG- IUS), are relatively contraindicated in women with 
breast cancer, particularly those with oestrogen receptor positive cancer, and it is usually discontin-
ued. Women may not want to start a new form of contraception whilst undergoing such major 
changes in their lives, therefore clinicians need to explain to patients the importance of contracep-
tion during breast cancer treatment and then plan for long-term contraception after definitive treat-
ment, particularly in those women who have completed their family or do not wish to conceive. 
Oncologists are not necessarily experts on long-term methods of contraception and women may 
benefit from referral to gynaecologists. Moreover, better education should be given to general prac-
titioners on contraceptive methods after malignancy as they are the first port of call for the patient 
for long-term or ongoing contraceptive advice. The current guideline of Faculty of Sexual and Re-
productive Health on contraceptive choices after treatment of breast cancer recommends non-
hormonal methods [32].  
 Use of Levonorgestrel Intrauterine System (LNG-IUS) is not usually recommended during breast 
cancer treatment, but can be used post breast cancer treatment with specialist advice sought if other 
more appropriate methods are not available or not acceptable. Table 3 outlines the different meth-
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ods of contraception and their pros and cons, this is adapted from the Faculty of Sexual and Repro-
ductive Healthcare guidelines. 
 The limitation of our study was that this was a retrospective questionnaire relying on women to re-
call facts from sometimes many years ago, and was therefore subject to recall and self-reporting 
bias. Although the data was collected from a large tertiary unit with a diverse population, the cohort 
was still limited to those patients living in the South East of England.    
This study has highlighted the importance of ongoing fertility counselling in those women who 
wish to conceive, and in particular contraceptive counselling in those who do not. We must 
adopt an approach of having frank discussions with our patients at the time of diagnosis, and on 
follow-up, so we are able to tailor their treatment to encompass issues of fertility and prevent 
unintended pregnancies.  
Specific questions and information regarding fertility and contraception should be part of the rou-
tine follow-up care and information offered to all patients of reproductive age following treatment 
for breast cancer. 
 
Disclosure: The authors have declared no conflicts of interest 
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Table 1 Characteristics of respondents 
 
Age of patients at the time of 
cancer diagnosis  
 
Median age, years 
Range 
37 
25 to 42 
 
Time since diagnosis     
Median, years  
Range 
6 
1 to 21 
    
Age of patients at the time of 
questionnaire  
  
Median age, years  43  
Range, years  30-55  
Menstrual function at diagnosis N=175  
Had periods  
Peripartum 
No periods 
Not answered 
 
158 (90%) 
4 (2%) 
4 (2%) 
9 (5%) 
 
Menstrual function after 
chemotherapy (n=131) 
N=131  
Periods restarted after chemo 
Periods did not restart after 
periods 
Periods not affected by chemo 
(did not stop) 
Not answered 
74 (56%) 
 
28 (21%) 
21 (16%) 
 
8 (6%) 
 
Previous pregnancies before 
cancer diagnosis 
N=175  
No 
Yes 
Not answered 
51(29%) 
113 (65%) 
11 (6%) 
 
Previous live birth 87 (50%)  
Treatment of breast cancer 
(reported by patients) 
   
Chemotherapy for treatment 
reported by patients 
131 (75%)  
Current Anti-estrogen Therapy  
Yes 
No 
Not answered 
 
57 (33%) 
106 (60%) 
12 (7%) 
 
 
 
 
 
Table
  
 
Table 2 Intention to conceive and reported contraception usage 
Intention to 
conceive 
Contraception 
reported 
No 
contraception 
Not answered Total 
Yes 4 (15%) 22 (81%) 1 (0.04%) 27 (15%) 
No 36 (32%) 74 (67%) 1 (1%) 111 (63%) 
Not answered 3 (4%) 9 (36%) 13 (52%) 25 (14%) 
Not applicable 1 (8%) 11 (92%) 0  12 (7%) 
Total 44 (25%) 116 (66%) 15(9%) 175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3: Summary of different methods of contraception available adopted from the Faculty 
of Sexual and Reproductive Healthcare Guidelines   https://www.fsrh.org/home/ 
Type of Contraception  Positives  Negatives 
Condoms  Low failure rate  
Cheap  
Protects against sexually 
transmitted infections 
Not long-acting form of 
contraception  
Caps  Can be inserted and removed by 
patient themselves  
Not readily available 
Must not be removed until 6 hours 
post coitus 
Expensive  
Copper IUD Long term form of contraception  
 
Can be used with breast cancer 
treatment 
Can cause menorrhagia, 
dysmenorrhoea 
 
Invasive  
LNG-IUS (levonorgestrel- 
intrauterine system) 
Long term form of contraception  
 
Counteracts the proliferation 
effects of tamoxifen in 
endometrium 
 
Can reduce menorrhagia  
Little data on use and recurrence 
of breast cancer.  
 
Specialist opinion should be 
sought before use in past history 
of breast cancer.  
 
Contraindicated in current breast 
cancer treatment  
 
Progestrone only Implant   Contraindicated in current breast 
cancer treatment  
 
Specialist opinion should be 
sought before use in past history 
of breast cancer.  
Depot medroxyprogesterone 
acetate   
 Contraindicated in current breast 
cancer treatment.  
 
Specialist opinion should be 
sought before use in past history 
of breast cancer.  
Progestogen only pill  Contraindicated in current breast 
cancer treatment.  
 
Specialist opinion should be 
sought before use in past history 
of breast cancer.  
  
 
 
 
Combined hormonal 
contraception  
 Contraindicated in current breast 
cancer treatment.  
 
Specialist opinion should be 
sought before use in past history 
of breast cancer.  
	
	
	
	
Figure 1 Intention to conceive after cancer treatment 
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Figure 2 Pregnancy outcomes in breast cancer patients after 
treatment. 	
	
	
	
	
	
*Some patients had more than one pregnancy that result in miscarriage or live birth	
	
	
Total	number	of	patients	
that	filled	in	questionaire		
n=175	
27	(17%=27/163)	
tried	to	conceiv	
13	(48%)	achieved	
live	birth	
6	miscarriages*		
2	currently	
pregnant	
111	(	68%=27/163)	
did	not	try	to	
conceive	
12	pregnancies	(11%)	
3	live	birth;	2	
miscarriages	
7	terminations		
25	(15%=25/163)	
did	not	answer		
12	-	not	possible	or	didnt	want	to	
attempt		
pregnancy	since	Ca	tx	
